Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)

PATRIK PALACKA; JAN SLOPOVSKY; JANA OBERTOVA; MICHAL CHOVANEC; KATARINA REJLEKOVA; ZUZANA SYCOVA-MILA; BORIS KOLLARIK; JOZEF MARDIAK; MICHAL MEGO

doi:10.21873/anticanres.15391

Research ArticleClinical Studies

Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)

PATRIK PALACKA, JAN SLOPOVSKY, JANA OBERTOVA, MICHAL CHOVANEC, KATARINA REJLEKOVA, ZUZANA SYCOVA-MILA, BORIS KOLLARIK, JOZEF MARDIAK and MICHAL MEGO

Anticancer Research November 2021, 41 (11) 5749-5759; DOI: https://doi.org/10.21873/anticanres.15391

PATRIK PALACKA

12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;

2National Cancer Institute, Bratislava, Slovak Republic;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: pal_patrick@yahoo.co.uk

JAN SLOPOVSKY

12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;

2National Cancer Institute, Bratislava, Slovak Republic;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

JANA OBERTOVA

12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;

2National Cancer Institute, Bratislava, Slovak Republic;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MICHAL CHOVANEC

12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;

2National Cancer Institute, Bratislava, Slovak Republic;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KATARINA REJLEKOVA

12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;

2National Cancer Institute, Bratislava, Slovak Republic;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

ZUZANA SYCOVA-MILA

2National Cancer Institute, Bratislava, Slovak Republic;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

BORIS KOLLARIK

3Department of Urology, University Hospital in Bratislava, Bratislava, Slovak Republic

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

JOZEF MARDIAK

12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;

2National Cancer Institute, Bratislava, Slovak Republic;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MICHAL MEGO

12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;

2National Cancer Institute, Bratislava, Slovak Republic;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

PreviousNext

In this issue

Anticancer Research

Vol. 41, Issue 11

November 2021

Table of Contents
Table of Contents (PDF)
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 3 + 8 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)